Abstract:OBJECTIVE:To investigate the clinical value of 18F-fluorodeoxyglucose (18F-FDG) coincidence SPECT imaging versus computed tomography (CT) for malignant lymphoma in the initial staging, early response to therapy, evaluation after completion of therapy and long-term follow-up.METHODS:18F-FDG SPECT scans was performed on 61 patients with pathologically proven malignant lymphoma. The mean age of this series was 55 years ranged from 12 to 85 years. The data of these patients were retrospectively analyzed, and the result of 18F-FDG SPECT scan was compared with the CT imaging result performed within 2 weeks before or after FDG scan. 161 18F-FDG SPECT scans were performed for initial tumor staging (n=61), early response to therapy (n=42), evaluation after completion of therapy (n=26) and long-term follow-up (n=32). Each patient had a follow-up >6 months.RESULTS:(1) Compared with CT scan, 18F-FDG SPECT imaging accurately upstaged the disease for 34.4% (21/61) of these patients at initial staging. It detected the lesions which were undetected by CT including bone marrow infiltration (n=17), foci of lymph node (n=3) and liver involvement (n=1). However, 3 patients were incorrectly staged, either downstaged or upstaged by 18F-FDG SPECT imaging. Of 212 lesions in 61 patients, 18-FDG SPECT imaging detected more lesions than CT (P < 0.01). The correspondence rate of '18-FDG SPECT imaging with marrow histology was 80.3% (49/61). (2) In early evaluation of the response to treatment, the accuracy, positive predictive value and negative predictive value of 18F-FDG SPECT imaging was 85.7%, 92.0% and 76.5% respectively, which is much higher than that of CT (64.3%, 75.0% and 50.0%), therefore, the therapeutic scheme in 21.4% (9/42) of these patients was changed by 18F-FDG SPECT imaging. Of 17 cases with negative 18F-FDG SPECT scan in early evaluation of therapy, clinical remission (13 complete remission and 3 partial remission) were achieved in 16 patients. Of the 25 patients with positive ones, 13 were considered as having progressive disease. (3) In the evaluation at the end of therapy or during follow-up, 58 18F-FDG SPECT imagings were performed in 26 patients. The specificity and positive predictive value were 85.7% and 68.4% versus 59.5% and 43.3%, respectively, by CT scan. Of 14 patients with residual masses detected by CT scan, 8 were diagnosed as complete remission (CR) by 18F-FDG SPECT imaging based on persistently negative FDG scans; The other 6 were interpreted as CR (n=1), partial remission (PR, n=2), non-remission (n=1) and progressive disease (n=2), thus there was only one false-positive FDG scan in these 14 patients.CONCLUSION:18F-FDG imaging is quite effective and superior to CT scan for malignant lymphoma in initial staging, evaluation of early response to therapy and after completion of therapy, and long-term follow-up, especially for evaluating the residual masse.

[Evaluation of Fluorodeoxyglucose-Position-emission Tomography-Computer Tomography Imaging on Head and Neck Squamous Cell Carcinomas Including Primary Tumors and Lymph Node Metastases].

18F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor

Clinical Significance of FDG Single-Photon Emission Computed Tomography: Computed Tomography in the Diagnosis of Head and Neck Cancers and Study of Its Mechanism.

[Value of 18F-FDG Metabolic Imaging in Diagnosis and Treatment of Head and Neck Tumors and Its Mechanism Study].

Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT

Accuracy of 18 F-FDG PET/CT in Detection of Neck Metastases of Oral Squamous Cell Carcinoma in Patients Without Large Palpable Lymph Nodes.

Evaluation of 18F-FDG imaging of coincidence SPECT in head and neck lesions

Standard uptake value of 18F-FDG in diagnosis of oral squamous cell carcinoma and cervical lymphonode metastatic squamous cell carcinoma

Comparative analysis of PET/CT and PET/MR image characteristics of head and neck squamous cell carcinoma

The Diagnosis of 18 F-fluorodexoxyglucose and 11C-Acetate PET/CT Scanning in Primary Liver Tumors and Tumor-Like Diseases : a Preliminary Study

(18)FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis.

Comparison of 18F-FDG Coincidence SPECT Imaging and Computed Tomography in the Initial Staging and Therapeutic Evaluation of Lymphomas

Diagnostic Accuracy of [18F]FDG 18 F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis

Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography for the Identification of Cervical Nodal Metastases of Head and Neck Cancer Compared with Computed Tomography/magnetic Resonance Imaging and Clinical Palpation in 40 Cases

An Analysis of 18F-Fluorodexyglucose (18F-FDG) Positron Emission Tomography on Monitoring Therapeutic Outcome in 21 Case with Nasopharyngeal Carcinoma after Radiotherapy

Diagnostic Accuracy of [18F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis

18 F-fludeoxyglucose positron emission computed tomography (18 F-FDG-PET/CT) versus 68 Ga-DOTATATE-PET/CT in patients with head and neck cancer: Comparisons and implications for treatment

[The Clinical Application of 18F-Fluorodeoxyglucose Coincidence Imaging in Lymphoma].

Retrospective analysis of 116 patients and diagnostic value of 18F-FDG PET/CT in hepatic tumor

18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization.

CLINICAL APPLICATION AND VALUE OF FDG PET/CT IN EVALUATION OF LYMPHATIC METASTASIS OF BREAST CANCER AFTER TREATMENT